Literature DB >> 16600690

Hydroxychloroquine-induced restrictive cardiomyopathy.

John Cotroneo1, Khaled M Sleik, E Rene Rodriguez, Allan L Klein.   

Abstract

Chloroquine (Hydroxychloroquine)-induced cardiomyopathy is a rare but potentially life-threatening condition. Cessation of the culprit drug, along with aggressive afterload reduction therapy, has been associated with halting of disease progress and even improvement in patients' clinical and histologic status. Echocardiography is a fundamental tool in the identification and assessment of patients with cardiomyopathy, with particular utility in the detailed assessment of biventricular systolic and diastolic function. It also provides an objective and non-invasive means of assessing treatment response. We present a case of a 51-year-old woman with hydroxychloroquine-induced restrictive cardiomyopathy and correlate clinical, echocardiographic and anatomic pathologic findings both at initial presentation and following treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16600690     DOI: 10.1016/j.euje.2006.02.002

Source DB:  PubMed          Journal:  Eur J Echocardiogr        ISSN: 1532-2114


  13 in total

1.  Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.

Authors:  Clotilde Chatre; François Roubille; Hélène Vernhet; Christian Jorgensen; Yves-Marie Pers
Journal:  Drug Saf       Date:  2018-10       Impact factor: 5.606

Review 2.  Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies.

Authors:  Matxalen Amezaga Urruela; Maria E Suarez-Almazor
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

3.  Cardiotoxicity after low-dose chloroquine antimalarial therapy.

Authors:  Gabriele Fragasso; Francesca Sanvito; Francesca Baratto; Sabina Martinenghi; Claudio Doglioni; Alberto Margonato
Journal:  Heart Vessels       Date:  2009-09-27       Impact factor: 2.037

4.  Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review.

Authors:  Emer Joyce; Aurelie Fabre; Niall Mahon
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2013-03

Review 5.  Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.

Authors:  Domenico Plantone; Tatiana Koudriavtseva
Journal:  Clin Drug Investig       Date:  2018-08       Impact factor: 3.580

6.  Use of Hydroxychloroquine and Risk of Heart Failure in Patients With Rheumatoid Arthritis.

Authors:  Ahmed A Sorour; Reto D Kurmann; Youssef E Shahin; Cynthia S Crowson; Sara J Achenbach; Rekha Mankad; Elena Myasoedova
Journal:  J Rheumatol       Date:  2021-01-15       Impact factor: 5.346

Review 7.  Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review.

Authors:  Anwar M Hashem; Badrah S Alghamdi; Abdullah A Algaissi; Fahad S Alshehri; Abdullah Bukhari; Mohamed A Alfaleh; Ziad A Memish
Journal:  Travel Med Infect Dis       Date:  2020-05-06       Impact factor: 6.211

Review 8.  Expanding horizons for clinical applications of chloroquine, hydroxychloroquine, and related structural analogues.

Authors:  Ashutosh M Shukla; Aparna Wagle Shukla
Journal:  Drugs Context       Date:  2019-11-25

9.  Hypertrophic cardiomyopathy in a lupus patient: a case of hydroxychloroquine cardiotoxicity.

Authors:  Amanda Chang; Gabriel Stolin; Judith Fan; Boris R Larreta; Gregory A Fishbein; William Dean Wallace; Arnold S Baas; Daniel Cruz; Jessica Wang
Journal:  ESC Heart Fail       Date:  2019-09-07

Review 10.  Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.

Authors:  Pankaj Bansal; Amandeep Goyal; Austin Cusick; Shubham Lahan; Harpal S Dhaliwal; Poonam Bhyan; Pradnya Brijmohan Bhattad; Fawad Aslam; Sagar Ranka; Tarun Dalia; Lovely Chhabra; Devang Sanghavi; Bhavin Sonani; John M Davis
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.